Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12403
Title: Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects.
Authors: Conway, Elizabeth L;McNeil, John J;Meng, L;Drummer, Olaf H;Howes, L G;Raymond, K;Louis, William J
Affiliation: University of Melbourne, Clinical Pharmacology and Therapeutics Units, Austin Hospital, Heidelberg, Victoria, Australia.
Issue Date: 1-Jun-1989
Citation: Clinical Pharmacokinetics; 16(6): 387-91
Abstract: The pharmacokinetics of doxazosin were determined in hypertensive subjects after a single dose of 1 mg, and at steady-state while receiving doses of 1, 2, 4 and 8 mg of the drug daily. Chlorothiazide 500 mg once daily was administered as additional therapy throughout the study. After a single dose doxazosin was rapidly absorbed, with peak plasma drug concentrations (Cmax) occurring after 2.1 +/- 0.4 hours. The elimination half-life in plasma was 10.7 +/- 1.2 hours. These parameters remained essentially unchanged during maintenance administration of doxazosin at each of the dose levels. Calculations of Cmax and area under the concentration-time curve (AUC0----infinity) indicated that the pharmacokinetic disposition of the drug remained linear over the dose range 1 to 8 mg.
Internal ID Number: 2525447
URI: http://ahro.austin.org.au/austinjspui/handle/1/12403
DOI: 10.2165/00003088-198916060-00004
URL: http://www.ncbi.nlm.nih.gov/pubmed/2525447
Type: Journal Article
Subjects: Adult
Aged
Antihypertensive Agents.adverse effects.pharmacokinetics.therapeutic use
Blood Pressure.drug effects
Chlorothiazide.adverse effects.pharmacokinetics.therapeutic use
Doxazosin
Female
Half-Life
Humans
Hypertension.drug therapy.metabolism.physiopathology
Male
Middle Aged
Prazosin.adverse effects.analogs & derivatives.pharmacokinetics.therapeutic use
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
2525447.pdf44.3 kBAdobe PDFView/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.